Abstract
What are the resources needed by clinical pharmacology to test drugs in ways that model how the practitioner achieves optimal effectiveness and safety with each patient? I describe the applications of test-retest standard error of measurement, clinical decision rules, means or other statistical summaries of observations, clinical trial designs that use each patient as her own control, and methods to control observer and site variance as steps for developing a CT tested model for optimal clinical uses of an Alzheimers drug by a practitioner. Many investigators and clinicians have been concerned with clinical judgments being scientifically uncontrolled and unsystematic. The methods I describe demonstrate how clinical trials can be used to overcome these limitations in current patient care. “Darwin showed that one simply could not understand evolution as long as one accepted essentialism. Species and populations are not types, they are not essentialistically defined classes, but rather are biopopulations composed of genetically unique individuals” E. Mayr [1].
Keywords: Alzheimer disease, Darwinian Biological Thinking, random measurement errors, standard error of measurement, Placebo
Current Alzheimer Research
Title: Lessons from Darwin: 21st Century Designs for Clinical Trials
Volume: 4 Issue: 4
Author(s): Robert E. Becker
Affiliation:
Keywords: Alzheimer disease, Darwinian Biological Thinking, random measurement errors, standard error of measurement, Placebo
Abstract: What are the resources needed by clinical pharmacology to test drugs in ways that model how the practitioner achieves optimal effectiveness and safety with each patient? I describe the applications of test-retest standard error of measurement, clinical decision rules, means or other statistical summaries of observations, clinical trial designs that use each patient as her own control, and methods to control observer and site variance as steps for developing a CT tested model for optimal clinical uses of an Alzheimers drug by a practitioner. Many investigators and clinicians have been concerned with clinical judgments being scientifically uncontrolled and unsystematic. The methods I describe demonstrate how clinical trials can be used to overcome these limitations in current patient care. “Darwin showed that one simply could not understand evolution as long as one accepted essentialism. Species and populations are not types, they are not essentialistically defined classes, but rather are biopopulations composed of genetically unique individuals” E. Mayr [1].
Export Options
About this article
Cite this article as:
Becker E. Robert, Lessons from Darwin: 21st Century Designs for Clinical Trials, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788828
DOI https://dx.doi.org/10.2174/156720507781788828 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
Current Neuropharmacology SkQ-1 Regulates Xanthine Oxidase Activity in the Settings of Epilepsic Seizures in Rats
Neuroscience and Biomedical Engineering (Discontinued) Calcium Homeostasis Following Traumatic Neuronal Injury
Current Neurovascular Research Novel Technologies for Dipeptide Drugs Design and their Implantation
Current Pharmaceutical Design The Differences in Neural Response to Faces and Non-Faces in the FFA: Evidence from the Central to Peripheral Visual Field
Neuroscience and Biomedical Engineering (Discontinued) A QSAR Study on Some Series of Sodium and Potassium Channel Blockers
Medicinal Chemistry Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?
Current Pharmaceutical Design Transcranial Magnetic Stimulation in Clinical Pharmacology
Central Nervous System Agents in Medicinal Chemistry Epidemiology of Psychotic Symptoms during Pregnancy and Postpartum in Women with Schizophrenia
Current Women`s Health Reviews Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Stem Cells and Cardiovascular Repair: A Role for Natural and Synthetic Molecules Harboring Differentiating and Paracrine Logics
Cardiovascular & Hematological Agents in Medicinal Chemistry Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012
Current Drug Research Reviews Molecular Mechanisms Underlying Behavioral Effects of Cocaine: Lessons From Knockout Mice
Current Pharmacogenomics Pathophysiology and Treatment of Nonfamilial Hyperparathyroidism
Recent Patents on CNS Drug Discovery (Discontinued) Signal Transduction by the Cytoplasmic Domain of NEUREGULIN-1 and its Roles During Neuronal Aging
Current Signal Transduction Therapy Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Drosophila Models of Proteinopathies: the Little Fly that Could
Current Pharmaceutical Design The Transcriptional Regulation of the Human CYP2C Genes
Current Drug Metabolism Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects
Current Bioinformatics An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
Current Pharmaceutical Design